TY  - JOUR
AU  - Garassino, Marina C.
AU  - Broggini, Massimo
PY  - 2015
TI  - Chemotherapy versus tyrosine kinase inhibitor in EGFR unselected population advanced non-small cell lung cancer still matter of debate?—An update incorporating the DELTA trial data
JF  - Journal of Thoracic Disease; Vol 7, No 3 (March 30, 2015): Journal of Thoracic Disease
Y2  - 2015
KW  - 
N2  - At present, for the treatment of second line advanced nonsmall cell lung cancer (NSCLC), three drugs are now available, pemetrexed, docetaxel and erlotinib (1-3). Docetaxel was registered in a superiority trial over placebo and it became the first second line approved at the beginning of this century, while erlotinib was licensed with a pivotal trial against placebo five years later (2).
UR  - https://jtd.amegroups.org/article/view/4073